SCHEMBL25366114

SCHEMBL25366114

OCc1cc(F)c(OCc2ccccc2)c(F)c1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 8/20 0.47
MAOA P21397 2/20 0.47
MAOB P27338 2/20 0.47
GLRA1 P23415 1/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
LMNA P02545 2/20 0.39
HPGD P15428 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
SLC6A2 P23975 2/20 0.39
SLC6A3 Q01959 2/20 0.39
CYP1A2 P05177 1/20 0.39
PTGS1 P23219 1/20 0.39
CYP2C19 P33261 1/20 0.39
PTGS2 P35354 1/20 0.39
HIF1A Q16665 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
HTR1A P08908 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25359554 0.82 KDM1A (0.49) KDM1AMAOAMAOBLMNAHPGD
SCHEMBL2303383 0.80 KDM1A (0.48) KDM1AMAOAMAOBCYP4F2CYP4A11
SCHEMBL30141114 0.80 ELANE (0.45) LMNAHTR1A
SCHEMBL24983670 0.80 ELANE (0.45) LMNAHTR1A
SCHEMBL23112086 0.79 KDM1A (0.46) KDM1AMAOAMAOBLMNAHPGD
SCHEMBL30765211 0.79 KDM1A (0.46) KDM1AMAOAMAOBLMNAHPGD
SCHEMBL6036178 0.78 KDM1A (0.51) KDM1AMAOAMAOBCYP4F2CYP4A11
SCHEMBL25365036 0.77 CTSV (0.52) LMNAHPGDTHRATHRB
SCHEMBL23111969 0.77 MEN1 (0.54) LMNAHPGD
SCHEMBL9823890 0.76 KDM1A (0.50) KDM1AMAOAMAOBLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083853-A1 HSD17B13 INHIBITORS AND USES THEREOF FL2022-001, INC. 2024-03-14 US disclosed
CN-116600801-A HSD17B13 inhibitors and uses thereof FL2022-001公司 2023-08-15 CN disclosed
EP-4221701-A1 HSD17B13 INHIBITORS AND USES THEREOF FL2022-001, Inc. (US) 2023-08-09 EP disclosed
WO-2022072491-A1 HSD17B13 INHIBITORS AND USES THEREOF METACRINE, INC. (US) 2022-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083853-A1 HSD17B13 INHIBITORS AND USES THEREOF HSD17B3, HSD17B11, HSD17B1 KDM1A 3306/4885MAOA 1287/4885MAOB 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.